{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:22:55Z","timestamp":1780521775159,"version":"3.54.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.cld.2023.07.003","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:55:30Z","timestamp":1693011330000},"page":"103-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of Primary Biliary Cholangitis including Transplantation"],"prefix":"10.1016","volume":"28","author":[{"given":"Yasameen","family":"Muzahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Wakil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehak","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Pyrsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cld.2023.07.003_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.07.003_bib2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patient with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2023.07.003_bib3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1472-8206.2000.tb00446.x","article-title":"Ursodeoxycholic acid modulates cyclosporin A oral absorption in liver transplant recipients","volume":"14","author":"Caroli-Bosc","year":"2000","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.cld.2023.07.003_bib4","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1053\/j.gastro.2005.06.019","article-title":"Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy","volume":"129","author":"Kondrackiene","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2023.07.003_bib5","first-page":"188","article-title":"Therapie mit Ursodeoxychols\u00e4ure bei prim\u00e4r bili\u00e4rer Zirrhose w\u00e4hrend der Schwangerschaft [-Therapy with ursodeoxycholic acid in primary biliary cirrhosis in pregnancy-]","volume":"34","author":"Rudi","year":"1996","journal-title":"Z\u00a0Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2023.07.003_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver","volume":"32","author":"Par\u00e9s","year":"2000","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2023.07.003_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jhep.2020.03.043","article-title":"Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis","volume":"73","author":"Corpechot","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2023.07.003_bib8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2023.07.003_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2023.07.003_bib10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the american association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2023.07.003_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/17512433.2015.1092381","article-title":"Obeticholic acid for the treatment of primary biliary cirrhosis","volume":"9","author":"Trivedi","year":"2016","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.cld.2023.07.003_bib12","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"Kowdley KV A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2023.07.003_bib13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jhep.2009.11.027","article-title":"Primary biliary cirrhosis: a 2010 update","volume":"52","author":"Poupon","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2023.07.003_bib14","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2023.07.003_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/HMER.S205431","article-title":"Update on emerging treatment options for primary biliary cholangitis","volume":"12","author":"Aguilar","year":"2020","journal-title":"Hepatic Med"},{"key":"10.1016\/j.cld.2023.07.003_bib16","doi-asserted-by":"crossref","first-page":"100188","DOI":"10.1016\/j.jtauto.2023.100188","article-title":"PPAR agonists for the treatment of primary biliary cholangitis: old and new tales","volume":"6","author":"Colapietro","year":"2023","journal-title":"Journal of translational autoimmunity"},{"key":"10.1016\/j.cld.2023.07.003_bib17","doi-asserted-by":"crossref","first-page":"940688","DOI":"10.3389\/fimmu.2022.940688","article-title":"Peroxisome proliferator-activated receptors regulate hepatic immunity and assist in the treatment of primary biliary cholangitis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cld.2023.07.003_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221114198","article-title":"A\u00a0randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid","volume":"13","author":"Li","year":"2022","journal-title":"Therapeutic advances in chronic disease"},{"issue":"4","key":"10.1016\/j.cld.2023.07.003_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"10.1016\/j.cld.2023.07.003_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/hepr.12373","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: a meta-analysis","volume":"45","author":"Zhang","year":"2015","journal-title":"Hepatology research"},{"issue":"6","key":"10.1016\/j.cld.2023.07.003_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatology research"},{"issue":"5","key":"10.1016\/j.cld.2023.07.003_bib22","first-page":"489","article-title":"Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials","volume":"32","author":"Agrawal","year":"2019","journal-title":"Annals of gastroenterology"},{"key":"10.1016\/j.cld.2023.07.003_bib23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"The open cardiovascular medicine journal"},{"issue":"6","key":"10.1016\/j.cld.2023.07.003_bib24","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A\u00a0randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.07.003_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fmed.2020.00117","article-title":"New therapeutic targets in autoimmune cholangiopathies","volume":"7","author":"Gerussi","year":"2020","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.cld.2023.07.003_bib26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2023.07.003_bib27","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2023.07.003_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.07.003_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2019.04.005","article-title":"Therapeutic trials of biologics in primary biliary cholangitis: an open label study of abatacept and review of the literature","volume":"101","author":"Bowlus","year":"2019","journal-title":"J\u00a0Autoimmun"},{"issue":"4","key":"10.1016\/j.cld.2023.07.003_bib30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"issue":"4 Pt B","key":"10.1016\/j.cld.2023.07.003_bib31","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbadis.2017.07.026","article-title":"Pathogenesis of biliary fibrosis. Biochimica et biophysica acta","volume":"1864","author":"Pinzani","year":"2018","journal-title":"Molecular basis of disease"},{"key":"10.1016\/j.cld.2023.07.003_bib32","doi-asserted-by":"crossref","first-page":"7831165","DOI":"10.1155\/2022\/7831165","article-title":"Pretransplant evaluation and liver transplantation outcome in PBC patients","volume":"2022","author":"Mijic","year":"2022","journal-title":"Canadian journal of gastroenterology & hepatology"},{"issue":"2","key":"10.1016\/j.cld.2023.07.003_bib33","first-page":"66","article-title":"Primary biliary cirrhosis and liver transplantation","volume":"1","author":"Akamatsu","year":"2012","journal-title":"Intractable & rare diseases research"},{"issue":"2","key":"10.1016\/j.cld.2023.07.003_bib34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL clinical practice guidelines: liver transplantation","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2023.07.003_bib35","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.cgh.2007.07.015","article-title":"Transplantation trends in primary biliary cirrhosis","volume":"5","author":"Lee","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2023.07.003_bib36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/jlts.2003.50096","article-title":"Recurrent primary biliary cirrhosis","volume":"9","author":"Neuberger","year":"2003","journal-title":"Liver Transplant"},{"issue":"3","key":"10.1016\/j.cld.2023.07.003_bib37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cld.2018.03.011","article-title":"Current status of liver transplantation for primary biliary cholangitis","volume":"22","author":"Aguilar","year":"2018","journal-title":"Clin Liver Dis"},{"issue":"4","key":"10.1016\/j.cld.2023.07.003_bib38","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-6143.2010.03038.x","article-title":"Recurrent primary biliary cirrhosis after liver transplantation","volume":"10","author":"Silveira","year":"2010","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.cld.2023.07.003_bib39","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/jlts.2003.50213","article-title":"Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history","volume":"9","author":"Sylvestre","year":"2003","journal-title":"Liver Transplant"},{"issue":"11","key":"10.1016\/j.cld.2023.07.003_bib40","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/01.TP.0000090867.83666.F7","article-title":"The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation","volume":"76","author":"Sanchez","year":"2003","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.cld.2023.07.003_bib41","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jhep.2015.07.038","article-title":"Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence","volume":"63","author":"Bosch","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2023.07.003_bib42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2036.2006.03223.x","article-title":"An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis","volume":"25","author":"Jones","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2023.07.003_bib43","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MJT.0000000000000387","article-title":"A\u00a0randomized, placebo-controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis","volume":"24","author":"Silveira","year":"2017","journal-title":"Am J Therapeut"},{"issue":"6","key":"10.1016\/j.cld.2023.07.003_bib44","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/hep.20698","article-title":"A\u00a0randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue","volume":"41","author":"Theal","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2023.07.003_bib45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2036.2003.01398.x","article-title":"Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial","volume":"17","author":"Prince","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.cld.2023.07.003_bib46","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/apt.13523","article-title":"Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis","volume":"43","author":"Kennedy","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2023.07.003_bib47","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJM196109072651004","article-title":"The treatment of pruritus and hypercholesteremia of primary biliary cirrhosis with cholestyramine","volume":"265","author":"Van Itallie","year":"1961","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.cld.2023.07.003_bib48","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","article-title":"The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus","volume":"102","author":"Tandon","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2023.07.003_bib49","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.23821","article-title":"The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kuiper","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2023.07.003_bib50","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/0016-5085(88)90442-8","article-title":"Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial","volume":"94","author":"Ghent","year":"1988","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.cld.2023.07.003_bib51","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1478-3231.2006.01326.x","article-title":"Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials","volume":"26","author":"Khurana","year":"2006","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.cld.2023.07.003_bib52","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/gut.50.3.436","article-title":"Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis","volume":"50","author":"Prince","year":"2002","journal-title":"Gut"},{"issue":"3 Pt 1","key":"10.1016\/j.cld.2023.07.003_bib53","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0190-9622(99)70117-9","article-title":"Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study","volume":"41","author":"Bergasa","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.cld.2023.07.003_bib54","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7326\/0003-4819-82-3-310","article-title":"Phenobarbital effects in cholestatic liver diseases","volume":"82","author":"Bloomer","year":"1975","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.cld.2023.07.003_bib55","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2023.07.003_bib56","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1572-0241.2004.30204.x","article-title":"Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis","volume":"99","author":"Par\u00e9s","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2023.07.003_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00365529709025067","article-title":"Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures","volume":"32","author":"Van Dam","year":"1997","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2023.07.003_bib58","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1136\/gut.2005.079814","article-title":"Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis","volume":"55","author":"Allocca","year":"2006","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.cld.2023.07.003_bib59","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/hepr.12452","article-title":"Coronary artery disease in primary biliary cirrhosis: a systematic review and meta-analysis of observational studies","volume":"45","author":"Ungprasert","year":"2015","journal-title":"Hepatol Res"},{"issue":"5","key":"10.1016\/j.cld.2023.07.003_bib60","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ajg.2010.102","article-title":"The myth of statin-induced hepatotoxicity","volume":"105","author":"Bader","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"31","key":"10.1016\/j.cld.2023.07.003_bib61","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.3748\/wjg.v24.i31.3513","article-title":"Osteoporosis in primary biliary cholangitis","volume":"24","author":"Danford","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2023.07.003_bib62","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.20866","article-title":"Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial","volume":"42","author":"Zein","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2023.07.003_bib63","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/hep.26466","article-title":"Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis","volume":"58","author":"Gua\u00f1abens","year":"2013","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2023.07.003_bib64","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2003.07639.x","article-title":"Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis","volume":"98","author":"Gua\u00f1abens","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2023.07.003_bib65","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10620-006-8015-x","article-title":"Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen\/progestin","volume":"51","author":"Boone","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.cld.2023.07.003_bib66","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/bjo.2005.070888","article-title":"Topical ciclosporin in the treatment of ocular surface disorders","volume":"89","author":"Tatlipinar","year":"2005","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.cld.2023.07.003_bib67","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12016-007-8008-3","article-title":"Conventional therapy of Sjogren's syndrome","volume":"32","author":"Mavragani","year":"2007","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:00:54Z","timestamp":1761069654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326123000831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1089326123000831"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.07.003","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Primary Biliary Cholangitis including Transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}